Shaan Dudani1, Guillermo de Velasco2, J Connor Wells1, Chun Loo Gan1, Frede Donskov3, Camillo Porta4,5, Anna Fraccon6, Felice Pasini7, Jae Lyun Lee8, Aaron Hansen9, Georg A Bjarnason10, Benoit Beuselinck11, Sumanta K Pal12, Takeshi Yuasa13, Nils Kroeger14, Ravindran Kanesvaran15, M Neil Reaume16, Christina Canil16, Toni K Choueiri17, Daniel Y C Heng1. 1. Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada. 2. Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain. 3. Department of Oncology,Aarhus University Hospital, Aarhus, Denmark. 4. Department of Internal Medicine, University of Pavia, Pavia, Italy. 5. Now with Department of Oncology, University of Bari Aldo Moro, Bari, Italy. 6. CDC Pererzoli, Peschiera del Garda, Italy. 7. Oncologia Medica Ospedale Santa Maria della Misericordia, Rovigo, Italy. 8. Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 9. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. 10. Division of Medical Oncology, Sunnybrook Research Institute, Toronto, Ontario, Canada. 11. Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium. 12. City of Hope Comprehensive Cancer Center, Duarte, California. 13. Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. 14. Department of Urology, University Medicine Greifswald, Greifswald, Germany. 15. Department of Medical Oncology, National Cancer Centre Singapore, Singapore. 16. The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada. 17. Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
Importance: There exists considerable biological and clinical variability between histologic variants of metastatic renal cell carcinoma (mRCC). Data reporting on patterns of metastasis in histologic variants of mRCC are sparse. Objective: To characterize sites of metastasis and their association with survival across the 3 most common histologic variants of mRCC: clear cell (ccRCC), papillary (pRCC), and chromophobe (chrRCC). Design, Setting, and Participants: In this multicenter, international cohort study, the International mRCC Database Consortium (IMDC) database was used to identify consecutive patients starting systemic therapy for mRCC between 2002 and 2019. Patients with mixed histologic subtype were excluded. Statistical analysis was performed from February to June 2020. Exposures: Data regarding histologic subtype and sites of metastatic involvement at the time of first systemic therapy initiation were collected. Main Outcomes and Measures: The primary outcomes were prevalence of metastatic site involvement and overall survival (OS) from time of systemic therapy initiation. Patients with multiple sites of metastatic involvement were included in analyses of all groups to which they had metastases. Results: A total of 10 105 patients were eligible for analysis. Median (interquartile range) age at diagnosis was 60 (53-67) years, 7310 (72.4%) were men and 8526 (84.5%) underwent nephrectomy. Of these, 9252 (92%) had ccRCC, 667 (7%) had pRCC, and 186 (2%) had chrRCC. The median number of sites of metastasis was 2 (range, 0-7). In ccRCC, the most common sites of metastasis were lung (70%; 6189 of 8804 patients [448 missing]), lymph nodes (45%; 3874 of 8655 patients [597 missing]), bone (32%; 2847 of 8817 patients [435 missing]), liver (18%; 1560 of 8804 [448 missing]), and adrenal gland (10%; 678 of 6673 patients [2579 missing]). Sites of metastasis varied between subtypes. Lung, adrenal, brain, and pancreatic metastases were more frequent in ccRCC, lymph node involvement was more common in pRCC, and liver metastases were more frequent in chrRCC. Median OS for ccRCC varied by site of metastatic involvement, ranging between 16 months (95% CI, 13.7-18.8 months) for the pleura and 50 months (95% CI, 41.1-55.5 months) for the pancreas. Compared with ccRCC, patients with pRCC tended to have lower OS, regardless of metastatic site. Conclusions and Relevance: Sites of metastatic involvement differ according to histologic subtype in mRCC and are associated with OS. These data highlight the clinical and biological variability between histologic subtypes of mRCC. Patterns of metastatic spread may reflect differences in underlying disease biology. Further work to investigate differences in immune, molecular, and genetic profiles between metastatic sites and histologic subtypes is encouraged.
Importance: There exists considerable biological and clinical variability between histologic variants of metastatic renal cell carcinoma (mRCC). Data reporting on patterns of metastasis in histologic variants of mRCC are sparse. Objective: To characterize sites of metastasis and their association with survival across the 3 most common histologic variants of mRCC: clear cell (ccRCC), papillary (pRCC), and chromophobe (chrRCC). Design, Setting, and Participants: In this multicenter, international cohort study, the International mRCC Database Consortium (IMDC) database was used to identify consecutive patients starting systemic therapy for mRCC between 2002 and 2019. Patients with mixed histologic subtype were excluded. Statistical analysis was performed from February to June 2020. Exposures: Data regarding histologic subtype and sites of metastatic involvement at the time of first systemic therapy initiation were collected. Main Outcomes and Measures: The primary outcomes were prevalence of metastatic site involvement and overall survival (OS) from time of systemic therapy initiation. Patients with multiple sites of metastatic involvement were included in analyses of all groups to which they had metastases. Results: A total of 10 105 patients were eligible for analysis. Median (interquartile range) age at diagnosis was 60 (53-67) years, 7310 (72.4%) were men and 8526 (84.5%) underwent nephrectomy. Of these, 9252 (92%) had ccRCC, 667 (7%) had pRCC, and 186 (2%) had chrRCC. The median number of sites of metastasis was 2 (range, 0-7). In ccRCC, the most common sites of metastasis were lung (70%; 6189 of 8804 patients [448 missing]), lymph nodes (45%; 3874 of 8655 patients [597 missing]), bone (32%; 2847 of 8817 patients [435 missing]), liver (18%; 1560 of 8804 [448 missing]), and adrenal gland (10%; 678 of 6673 patients [2579 missing]). Sites of metastasis varied between subtypes. Lung, adrenal, brain, and pancreatic metastases were more frequent in ccRCC, lymph node involvement was more common in pRCC, and liver metastases were more frequent in chrRCC. Median OS for ccRCC varied by site of metastatic involvement, ranging between 16 months (95% CI, 13.7-18.8 months) for the pleura and 50 months (95% CI, 41.1-55.5 months) for the pancreas. Compared with ccRCC, patients with pRCC tended to have lower OS, regardless of metastatic site. Conclusions and Relevance: Sites of metastatic involvement differ according to histologic subtype in mRCC and are associated with OS. These data highlight the clinical and biological variability between histologic subtypes of mRCC. Patterns of metastatic spread may reflect differences in underlying disease biology. Further work to investigate differences in immune, molecular, and genetic profiles between metastatic sites and histologic subtypes is encouraged.
Authors: Sarathi Kalra; Bradley J Atkinson; Marc Ryan Matrana; Surena F Matin; Christopher G Wood; Jose A Karam; Pheroze Tamboli; Kanishka Sircar; Priya Rao; Paul G Corn; Nizar M Tannir; Eric Jonasch Journal: BJU Int Date: 2015-07-06 Impact factor: 5.588
Authors: Jean-Jacques Patard; Emmanuelle Leray; Nathalie Rioux-Leclercq; Luca Cindolo; Vincenzo Ficarra; Amnon Zisman; Alexandre De La Taille; Jacques Tostain; Walter Artibani; Claude C Abbou; Bernard Lobel; François Guillé; Dominique K Chopin; Peter F A Mulders; Christopher G Wood; David A Swanson; Robert A Figlin; Arie S Belldegrun; Allan J Pantuck Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: Brian I Rini; Thomas Powles; Michael B Atkins; Bernard Escudier; David F McDermott; Cristina Suarez; Sergio Bracarda; Walter M Stadler; Frede Donskov; Jae Lyun Lee; Robert Hawkins; Alain Ravaud; Boris Alekseev; Michael Staehler; Motohide Uemura; Ugo De Giorgi; Begoña Mellado; Camillo Porta; Bohuslav Melichar; Howard Gurney; Jens Bedke; Toni K Choueiri; Francis Parnis; Tarik Khaznadar; Alpa Thobhani; Shi Li; Elisabeth Piault-Louis; Gretchen Frantz; Mahrukh Huseni; Christina Schiff; Marjorie C Green; Robert J Motzer Journal: Lancet Date: 2019-05-09 Impact factor: 79.321
Authors: Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier Journal: N Engl J Med Date: 2018-03-21 Impact factor: 91.245
Authors: B Beuselinck; S Oudard; O Rixe; P Wolter; A Blesius; J Ayllon; R Elaidi; P Schöffski; E Barrascout; A Morel; B Escudier; H Lang; J Zucman-Rossi; J Medioni Journal: Ann Oncol Date: 2010-10-11 Impact factor: 32.976
Authors: M Bianchi; M Sun; C Jeldres; S F Shariat; Q-D Trinh; A Briganti; Z Tian; J Schmitges; M Graefen; P Perrotte; M Menon; F Montorsi; P I Karakiewicz Journal: Ann Oncol Date: 2011-09-02 Impact factor: 32.976
Authors: Gwenaelle Gravis; Brice Chanez; Lisa Derosa; Benoit Beuselinck; Philippe Barthelemy; Brigitte Laguerre; Pierre-Emmanuel Brachet; Florence Joly; Bernard Escudier; David J Harrison; Alexander Laird; Naveen Vasudev; Christy Ralph; James Larkin; Hazel Lote; Naji Salem; Jochen Walz; Jeanne Thomassin; Patrick Sfumato; Grant D Stewart; Jean Marie Boher Journal: Urol Oncol Date: 2015-12-03 Impact factor: 3.498
Authors: Daniel N Cagney; Allison M Martin; Paul J Catalano; Amanda J Redig; Nancy U Lin; Eudocia Q Lee; Patrick Y Wen; Ian F Dunn; Wenya Linda Bi; Stephanie E Weiss; Daphne A Haas-Kogan; Brian M Alexander; Ayal A Aizer Journal: Neuro Oncol Date: 2017-10-19 Impact factor: 12.300
Authors: Alberto C Pieretti; Daniel D Shapiro; Mary E Westerman; Hyunsoo Hwang; Xuemei Wang; Luis A Segarra; Matthew T Campbell; Nizar M Tannir; Eric Jonasch; Surena F Matin; Christopher G Wood; Jose A Karam Journal: Urol Oncol Date: 2021-09-20 Impact factor: 2.954
Authors: Anna Voelker; Georg Osterhoff; Stefanie Einhorn; Sebastian Ebel; Christoph-Eckhard Heyde; Philipp Pieroh Journal: World J Surg Oncol Date: 2022-06-16 Impact factor: 3.253
Authors: Alberto C Pieretti; Manuel Ozambela; Mary E Westerman; Graciela M Nogueras-Gonzalez; Luis A Segarra; Niki M Zacharias; Ara Vaporciyan; Wayne Hofstetter; Tam Huynh; Saad Aldousari; Surena F Matin; Jose A Karam Journal: Clin Genitourin Cancer Date: 2022-02-09 Impact factor: 3.121
Authors: Jonathan E Schoenhals; Osama Mohamad; Alana Christie; Yuanyuan Zhang; Daniel Li; Nirmish Singla; Isaac Bowman; Waddah Arafat; Hans Hammers; Kevin Courtney; Suzanne Cole; Aditya Bagrodia; Vitaly Margulis; Neil Desai; Aurelie Garant; Hak Choy; Robert Timmerman; James Brugarolas; Raquibul Hannan Journal: Adv Radiat Oncol Date: 2021-05-26